Institutional Career Development Core

机构职业发展核心

基本信息

项目摘要

The KL2 program, established in 2010, has uniquely focused on high quality career development in clinical and translational research, engaging a diverse pool of faculty mentors and mentees across a range of disciplines to approach science through a “disease-agnostic” translational lens. This dynamic and responsive program is unlike any other at VCU and is an integrated and synergistic component of the CCTR and university-wide workforce development. The broad ranging CCTR educational programs and the KL2 will continue to expand research capacity in Virginia, nationally, and across the network of CTSA hubs capitalizing on strengths in Community Engaged Research, Team Science, and Informatics through the following specific aims: Aim 1: To provide an individually tailored, top-quality, mentored research experience that incorporates best practices in project development, implementation, analysis and presentation focusing on community engagement, team science, informatics, and translation. KL2 scholars are recruited from a robust and diverse pool of junior faculty within the research workforce pipeline at VCU, which include a number of feeder programs such as T-32 programs and the recently established Rising- and Emerging Scholar Programs. The feeder programs as well as the KL2 program also serve to recruit promising investigators to develop a research career at VCU. The program is supported by a senior leadership team and core mentors with a strong record of funding and mentorship. They are supported by CCTR personnel including a KL2 administrator who work closely with the scholars to develop and implement their IDP, monitor progress and help in the K-to-R transition. All scholars achieve core competencies in statistics, study design-analysis, community engagement, team science, and informatics in addition to expertise in their area of research. A robust evaluation process to monitor and provide feedback and guide strategic direction is in place. The strong workforce development environment at VCU supports the likelihood of success of KL2 scholars. Aim 2: To develop a career pathway for a diverse group of young investigators based on their current level of training that provides a transition to scientific independence. VCU provides an institutionally funded bookend program to maximize career development and enhance the value of the KL2 program by preparing not-yet-ready but promising faculty to be competitive for the KL2 award via the Emerging Scholar Program and a K-to-R transition award following completion of the KL2 program. The pathway for a KL2 scholar to obtain an R, an outside K, or other next-tier grant is mapped at the time of entry into the program.
KL2计划成立于2010年,专注于高质量的职业发展 临床和翻译研究,吸引了一群不同的教师导师和梅内特人 通过“疾病敏锐的”翻译镜头接近科学的一系列学科。这个动态 和响应式程序与VCU的任何其他计划都不一样,并且是集成和协同的组成部分 CCTR和大学范围内的劳动力发展。广泛的CCTR教育计划和 KL2将继续扩大弗吉尼亚州,全国和CTSA枢纽网络的研究能力 利用社区参与研究,团队科学和信息学的优势通过 遵循特定目的: 目标1:提供单独量身定制的高质量的讨论研究经验 将最佳实践纳入项目开发,实施,分析和演讲中 专注于社区参与,团队科学,信息信息和翻译。 KL2学者是从研究劳动力中的强大而潜水员的初级教师库中招募的 VCU的管道,其中包括许多馈线程序,例如T-32程序和最近 建立了上升和新兴的学者计划。馈线程序以及KL2程序也 为招募有前途的研究人员在VCU开发研究生涯。该程序由 高级领导团队和核心导师,具有丰富的资金和指导记录。他们得到了支持 由CCTR人员包括在内的KL2管理员,与学者紧密合作以开发和 实施其IDP,监视进度并在K-TO-R转型中提供帮助。所有学者都取得了核心 统计,研究设计分析,社区参与,团队科学和信息的能力 除了研究领域的专业知识。一个强大的评估过程,以监视和提供反馈 并指导战略方向。 VCU的强大劳动力发展环境支持 KL2学者成功的可能性。 目标2:根据他们 当前的训练水平,可以过渡到科学独立性。 VCU提供了一项由机构资助的书架计划,以最大程度地提高职业发展并增强 KL2计划的价值通过准备尚未准备就绪,但承诺教师对KL2奖的竞争力 通过新兴的学者计划和KL2计划完成后的K-TO-R转型奖。这 KL2科学获得R,外部K或其他下一级赠款的途径在进入时被绘制 进入程序。

项目成果

期刊论文数量(15)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Hypertension in Cancer Survivors: A Review of the Literature and Suggested Approach to Diagnosis and Treatment.
  • DOI:
    10.1097/fjc.0000000000001342
  • 发表时间:
    2022-10-01
  • 期刊:
  • 影响因子:
    3
  • 作者:
    Chuquin, David;Abbate, Antonio;Bottinor, Wendy
  • 通讯作者:
    Bottinor, Wendy
Reduced metabolic flexibility is a predictor of weight gain among liver transplant recipients.
代谢灵活性降低是肝移植受者体重增加的预测因素。
Functional Gene Variants in Chronic Obstructive Pulmonary Disease: The Search Continues.
2021 Update on Pediatric Overuse.
  • DOI:
    10.1542/peds.2021-053384
  • 发表时间:
    2022-02-01
  • 期刊:
  • 影响因子:
    8
  • 作者:
    Money, Nathan M. M.;Schroeder, Alan R. R.;Quinonez, Ricardo A. A.;Ho, Timmy;Marin, Jennifer R. R.;Wolf, Elizabeth R. R.;Morgan, Daniel J. J.;Dhruva, Sanket S. S.;Coon, Eric R. R.
  • 通讯作者:
    Coon, Eric R. R.
Examining fear of cancer recurrence in primary brain tumor patients and their caregivers using the Actor-Partner Interdependence Model.
  • DOI:
    10.1002/pon.5659
  • 发表时间:
    2021-07
  • 期刊:
  • 影响因子:
    3.6
  • 作者:
    Braun, Sarah Ellen;Aslanzadeh, Farah J.;Thacker, Leroy;Loughan, Ashlee R.
  • 通讯作者:
    Loughan, Ashlee R.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SERGE PATRICK NANASINKAM其他文献

SERGE PATRICK NANASINKAM的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SERGE PATRICK NANASINKAM', 18)}}的其他基金

CTSA K12 Program at Virginia Commonwealth University
弗吉尼亚联邦大学 CTSA K12 项目
  • 批准号:
    10619075
  • 财政年份:
    2023
  • 资助金额:
    $ 74.29万
  • 项目类别:
Project 1: Lung Cancer
项目一:肺癌
  • 批准号:
    10493289
  • 财政年份:
    2021
  • 资助金额:
    $ 74.29万
  • 项目类别:
Project 1: Lung Cancer
项目一:肺癌
  • 批准号:
    10290161
  • 财政年份:
    2021
  • 资助金额:
    $ 74.29万
  • 项目类别:
Institutional Career Development Core
机构职业发展核心
  • 批准号:
    9913602
  • 财政年份:
    2018
  • 资助金额:
    $ 74.29万
  • 项目类别:
MicroRNA Expression in Lung Cancer Development and Progression
肺癌发生和进展中的 MicroRNA 表达
  • 批准号:
    8021770
  • 财政年份:
    2010
  • 资助金额:
    $ 74.29万
  • 项目类别:
MicroRNA Expression in Lung Cancer Development and Progression
肺癌发生和进展中的 MicroRNA 表达
  • 批准号:
    7873350
  • 财政年份:
    2010
  • 资助金额:
    $ 74.29万
  • 项目类别:
Integration of transcriptosome and microRNome in Understanding COPD Phenotypes
转录体和 microRNome 的整合在理解 COPD 表型中的作用
  • 批准号:
    7690864
  • 财政年份:
    2008
  • 资助金额:
    $ 74.29万
  • 项目类别:
Regulation of Prostacyclin in Pulmonary Hypertension
前列环素在肺动脉高压中的调节
  • 批准号:
    6933068
  • 财政年份:
    2004
  • 资助金额:
    $ 74.29万
  • 项目类别:
Regulation of Prostacyclin in Pulmonary Hypertension
前列环素在肺动脉高压中的调节
  • 批准号:
    6817114
  • 财政年份:
    2004
  • 资助金额:
    $ 74.29万
  • 项目类别:
Regulation of Prostacyclin in Pulmonary Hypertension
前列环素在肺动脉高压中的调节
  • 批准号:
    7480211
  • 财政年份:
    2004
  • 资助金额:
    $ 74.29万
  • 项目类别:

相似海外基金

Improving Information Sharing Between Family Caregivers and Home Care Aides Caring for Persons Living with ADRD
改善照顾 ADRD 患者的家庭护理人员和家庭护理助理之间的信息共享
  • 批准号:
    10571144
  • 财政年份:
    2023
  • 资助金额:
    $ 74.29万
  • 项目类别:
AppalTRuST Administrative Core
AppalTrust 管理核心
  • 批准号:
    10665323
  • 财政年份:
    2023
  • 资助金额:
    $ 74.29万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10551704
  • 财政年份:
    2023
  • 资助金额:
    $ 74.29万
  • 项目类别:
Do Acquisitions of Hospice Agencies by Private Equity Firms and Publicly Traded Corporations Impact End-of-Life Quality and Cost of Care?
私募股权公司和上市公司收购临终关怀机构是否会影响临终护理质量和护理成本?
  • 批准号:
    10351004
  • 财政年份:
    2022
  • 资助金额:
    $ 74.29万
  • 项目类别:
Administration Core
行政核心
  • 批准号:
    10334203
  • 财政年份:
    2022
  • 资助金额:
    $ 74.29万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了